Morning Briefing

In this Atlantic opinion piece, Amanda Glassman, director of Global Health Policy at the Center for Global Development (CGD), reports on how "lengthy, inefficient review processes" or "non-existent regulatory capacity" in some developing countries for drug and vaccine candidates waiting in the pipeline is keeping new medicines, vaccines, and diagnostic techniques from reaching millions in need. Glassman highlights a number of trials that were delayed due to regulatory and ethical approval processes, writing, "Not only do these delays prevent access to effective treatments by a growing number of patients," but "they can lead to unnecessary costs that eat away at already small budgets to find new cures for neglected diseases."